Two news have kept Aurobindo Pharma in the deep green today morning.

First news – it has got the US FDA nod for its cholesterol drug, Ezetimibe tablet.

Second news – it is planning to buy the Russia business of Mumbai-based Shreya Life Sciences Pvt. Ltd; deal is valued at $80 million to $100 million.

The stock price is up, reacting positively to both these; going up almost 3% at Rs.750.60; it has come off this level since then and is now at Rs.743 levels.